A Pilot Study to Assess the Effects of Lubiprostone on Gastrointestinal and Colonic Motility and pH in Patients With the Irritable Bowel Syndrome and Constipation (IBS-C).
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Lubiprostone (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics
- Sponsors Takeda Pharmaceuticals USA
- 01 Dec 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2010 New trial record